AI-backed imaging and care coordination corporate Viz.ai is partnering with biotechnology corporate Regeneron and biopharmaceutical corporate Sanofi to deploy and learn about an AI-enabled workflow instrument for COPD.
Viz.ai gives a care coordination platform with greater than 50 FDA-cleared algorithms that lend a hand analyze clinical imaging information to supply insights into prognosis, streamline workflows and lend a hand with remedy choices.
The corporate gives AI-enabled neurology, trauma, cardiology, radiology and vascular care equipment.
During the partnership, Sanofi and Regeneron will give a boost to the corporate’s investigation of its Viz COPD Module, which employs AI and digital well being file information, the use of herbal language processing to stumble on and set up high-risk COPD sufferers.
COPD is a not unusual lung illness that reasons harm to the lungs and can lead to limited airflow and respiring issues.
“At Sanofi, we are excited to collaborate with Viz.ai to additional cope with unmet wishes in COPD care via leveraging AI,” Dr. Paul Rowe, ATSF and head of clinical and uniqueness care at Sanofi, stated in a observation.
“With this collaboration, we will be able to learn about the have an effect on of the Viz COPD module, a streamlined AI-enabled EHR workflow to make stronger get admission to to care and in the long run affected person results in COPD, a illness that is still under-prioritized, underfunded and undertreated compared to different noncommunicable illnesses.”
THE LARGER TREND
Previous this 12 months, Viz.ai introduced a collaboration with oncology-focused biotech corporate Guardant Well being to make use of AI and genomics to handle demanding situations in lung most cancers care.
In 2024, Viz.ai introduced a collaboration with Microsoft to supply its AI fashions throughout the tech large’s Precision Imaging Community, a part of Microsoft Cloud for Healthcare. The partnership, aimed toward bettering medical workflows for radiologists, noticed greater than 48 AI fashions built-in into Microsoft’s platform.
The corporate additionally introduced a lot of different collaborations, together with alliances with center assault prediction startup Cleerly and the Addario Lung Most cancers Scientific Institute, a nonprofit group that plays lung most cancers analysis.
In 2023, Viz.ai signed a multiyear settlement with international pharmaceutical corporate Bristol Myers Squibb to unencumber an AI-enabled set of rules and device for supplier workflow dubbed Viz HCM.
In 2022, Viz.ai secured $100 million in Collection D investment, bringing its valuation to $1.2 billion. The investment got here 12 months after the corporate closed its Collection C investment spherical value $71 million.
